Patent ID: 11858982
Assignee: MEDANNEX LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating cancer in a subject, comprising administering to said subject a specific antibody or fragment thereof which binds human Anx-A1 and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each of said CDRs having an amino acid sequence as follows:
VLCDR1 has the sequence set forth in SEQ ID NO: 1;
VLCDR2 has the sequence set forth in SEQ ID NO: 2;
VLCDR3 has the sequence set forth in SEQ ID NO: 3;
VHCDR1 has the sequence set forth in SEQ ID NO: 4;
VHCDR2 has the sequence set forth in SEQ ID NO: 5; and
VHCDR3 has the sequence set forth in SEQ ID NO: 6.